Dr. Robert D. Ross, MD
Ophthalmology (Ophthalmology Physician)
4224 Houma Blvd, Suite 430
Metairie, LA 70006
Who else practices at this address →
Jefferson Parish includes primary care (18% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- New York Medical College (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 498
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: New York Medical College
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
LA license 10706R · MS license 14895
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Hospital at Gulfport Gulfport, MS
- Singing River Gulfport Gulfport, MS
Medical groups
- Robert D. Ross, MD (apmc) (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 498
- Services billed
- 27,173
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 18,900 | 64 |
| Established patient complete exam of visual system | 1,680 | 508 |
| Imaging of retina | 1,648 | 522 |
| Photography of the retina | 1,308 | 513 |
| Injection of drug into eye | 705 | 112 |
| Extended exam of the back part of the eye with retinal drawing | 562 | 183 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 485 | 345 |
| Injection, aflibercept, 1 mg | 370 | 57 |
| Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye | 351 | 220 |
| Exam of the internal drainage system of eye | 187 | 170 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Moxifloxacin (moxifloxacin hcl) Other prescribers in Metairie, LA | 221 |
| Ketorolac Tromethamine Other prescribers in Metairie, LA | 163 |
| Prednisolone Acetate Other prescribers in Metairie, LA | 118 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Metairie, LA | 107 |
| Lotemax Sm (loteprednol etabonate) | 98 |
| Prolensa (bromfenac sodium) | 59 |
| Loteprednol Etabonate | 50 |
| Dorzolamide Hcl Other prescribers in Metairie, LA | 41 |
| Brimonidine Tartrate Other prescribers in Metairie, LA | 38 |
| Ofloxacin Other prescribers in Metairie, LA | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 19 payments worth $557 in total to this clinician.
| AbbVie Inc. | $167 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $123 |
| Regeneron Pharmaceuticals, Inc. | $119 |
| Mallinckrodt Hospital Products Inc. | $69.97 |
| Genentech USA, Inc. | $26.49 |
| Astellas Pharma US Inc | $20.78 |
| Ani Pharmaceuticals, Inc. | $15.48 |
| Neurotech Pharmaceuticals, Inc. | $14.70 |
| Food and Beverage | $557 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $28,390 in research payments for these studies, mostly to the institutions running them.
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.